HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker studyVivek Naranbhai, Mary Carrington, Mathias Viard et al.|The Lancet Oncology|2021Cited by 126
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitorsAmin H. Nassar, Alexander Gusev, Tomin Perea-Chamblee et al.|Cancer Cell|2022Cited by 117
Integrative clinical and molecular characterization of translocation renal cell carcinomaZiad Bakouny, Srinivas R. Viswanathan, Ananthan Sadagopan et al.|Cell Reports|2022Cited by 115
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Alexander Gusev, Sarah Abou Alaiwi et al.|Nature Medicine|2022Cited by 106